Morepen Laboratories

The average trading volumes at the Morepen Laboratories counter jumped more than two-fold with a combined 38.92 million shares changing hands on the NSE and BSE till 03:12 PM on Thursday.

Morepen Laboratories' share price hit a multi-year high of ₹112.85, soaring 8 per cent on the BSE in Wednesday's intra-day trade.

Morepen Laboratories today announced that its PAT surged by 394 per cent Y-o-Y to ₹56.35 crore in the June quarter, supported by better operating leverage and improved performance on API front.

At 01:13 PM on Tuesday; Nifty Pharma index, the top gainer among sectoral indices, was up 0.2 per cent, as compared to 1.1 per cent decline in the Nifty 50.

Over the past month, Morepen Laboratories has delivered a 34 per cent return, exceeding the Sensex's 2.2 per cent gain

Morepen Laboratories said supplies under the contract are expected to begin within the next four to five months, while execution is scheduled through the first quarter of the financial year 2026-27

Morepen Laboratories shares jumped 5.7 per cent, after the company arm Morepen Medipath executed a joint venture (JV) agreement with Bimedical FZE, a UAE based entity

Morepen Laboratories on Friday said it will add more than 1,000 medical representatives over the next three years, with over 200 team members expected to join in FY26 alone. The company aims to strengthen its formulations business in the market through new hirings. "This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market," Morepen Laboratories Chairman and MD Sushil Suri said in a statement. With significant increase in the sales force and enhanced reach to doctors, pharmacies, and patients, the drugmaker is setting the stage for getting a bigger pie in the Indian pharmaceutical market valued at Rs 2.38 lakh crore, yielding higher gross margins and better returns for stakeholders in the long run, he added. Currently, Morepen's formulation business stands around Rs 325 crore, and the company is targeting to touch Rs 1,000 crore in the next five years. This goal will be supported by an aggressive expans

The uptick in the Morepen Labs share came after the company announced that it has rolled out 'Empamore.'

Morepen Labs share price: Volumes on the Morepen Labs counter jumped suddenly around 1:05 PM with around 1.67 million shares changing hands in multiple tranches on the BSE

Company eyes Rs 30 crore revenue in first year, Rs 200 crore by 2030

Expanding capacities, backward integrating production and eyeing US market for exports

Earlier this month, the company had incorporated a wholly-owned subsidiary, Morepen RX.

Drug firm Morepen Laboratories on Thursday said its consolidated net profit declined by 55 per cent to Rs 12 crore for the fourth quarter ended March 2022.

Morepen's product is the generic version of Sanofi Aventis' anti- allergy drug.

Morepen Laboratories on Wednesday said its shareholders have approved to shift its medical devices business into a newly incorporated wholly-owned subsidiary

The approval of samples, licensing, and final production will take around two months and the vaccine would be available in India for sale also in two months, says CMD Sushil Suri

Drug firm Morepen Laboratories on Tuesday reported an over two-fold rise in its consolidated net profit at Rs 26.76 crore for the quarter ended March 31, 2021, on account of higher revenue

On April 28, Morepen Group sealed $100 million (Rs 750 crore approx.) investment from Corinth Group of Switzerland

Morepen Laboratories said its board has approved raising over Rs 433 crore through issue of shares to Switzerland's private venture capital firm Corinth Investment Holdings and Liquid Holdings